Strand Therapeutics, a clinical-stage biotechnology company pioneering programmable mRNA medicines, has appointed Kunal Bhatia as Chief Financial Officer (CFO). Bhatia brings 15 years of investment banking experience, driving fundraising, business development, and M&A for over 100 public and private biopharmaceutical companies. “With early validation of our platform in the clinic, we have built a pipeline from solid tumor immuno-oncology to systemic delivery to in vivo cell thera...